Skip to main content
Premium Trial:

Request an Annual Quote

Argonaut Shareholders Approve Purchase by Biotage of Portions of Company

NEW YORK, June 2 (GenomeWeb News) - A majority of Argonaut's shareholders have approved the acquisition of parts of the company by Biotage, according to a statement the companies released today.


Those portions -- Argonaut's reagents and process instruments business -- will officially be part of Biotage on June 3. Biotage will pay 155 MSEK ($20.9 million) for the components.


The acquisition is aimed at strengthening Biotage's offering in medicinal chemistry, according to Jeff Bork, president and CEO.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.